Human cytomegalovirus hyperimmune globulin not only neutralizes HCMV infectivity, but also inhibits HCMV-induced intracellular NF-κB, Sp1, and PI3-K signaling pathways

Journal of Medical Virology

Volumn 67, Issue 1, 2002, Pages 33-40

  Andreoni, Kenneth A ^a   Wang, Xin ^b   Huang, Shu Mei ^a   Huang, Eng Shang ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Cytomegalovirus; HCMV hyperimmune globulin; NF B; PI3 K signaling pathway; Sp1

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; CYTOMEGALOVIRUS VACCINE; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR SP1;

ANTIVIRAL ACTIVITY; ARTICLE; CELL PROLIFERATION; CYTOMEGALOVIRUS INFECTION; ELECTROPHORETIC MOBILITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMEDIATE EARLY GENE; POLYMERASE CHAIN REACTION; STRAIN DIFFERENCE; VIRUS INHIBITION; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS REPLICATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CAPSID; CAPSID PROTEINS; CYTOMEGALOVIRUS INFECTIONS; ENZYME ACTIVATION; HUMANS; IMMEDIATE-EARLY PROTEINS; IMMUNOGLOBULINS; INTRACELLULAR FLUID; MEMBRANE GLYCOPROTEINS; NEUTRALIZATION TESTS; NF-KAPPA B; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; SP1 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; VIRAL ENVELOPE PROTEINS; VIRAL PROTEINS;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 0036210333     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.2189     Document Type: Article

References (38)

1. Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase
2. Akt activation by growth factors is a multiple-step process: The role of the PH domain
3. Human cytomegalovirus induces expression of cellular topoisomerase II
4. Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication
5. Human cytomegalovirus infection results in altered Cdk2 subcellular localization
6. Human cytomegalovirus ie1 transactivates the alpha promoter-enhancer via an 18-base-pair repeat element
7. Stimulation of cellular thymidine kinases by human cytomegalovirus
8. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation
9. Phosphoinositide kinases
10. Characterization of human cytomegalovirus UL84 early gene and identification of its putative protein product
11. Human cytomegalovirus. III. Virus-induced DNA polymerase
12. Human cytomegalovirus. IV. Specific inhibition of virus-induced DNA polymerase activity and viral DNA replication by phosphonoacetic acid
13. Diagnosis of human cytomegalovirus infection: Laboratory approaches
14. Human cytomegalovirus. I. Purification and characterization of viral DNA
15. Inhibitory effect of 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole on HCMV DNA replication and permissive infection
16. Activation of the mitogen-activated protein kinase p38 by human cytomegalovirus infection through two distinct pathways: A novel mechanism for activation of p38
17. The role of MKK1/2 kinase activity in human cytomegalovirus infection
18. Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: Inhibition of PI3-K activity inhibits viral replication and virus-induced signaling
19. Productive infection of human endometrial stromal cells by human cytomegalovirus
20. Peripheral blood mononuclear cells (PBMNCs) augment the anti-viral effect of anti-cytomegalovirus (CMV) immunoglobulin
21. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro
22. Inhibition of cellular DNA polymerase alpha and human cytomegalovirus-induced DNA polymerase by the triphosphates of 9-(2-hydroxyethoxymethyl)-guanine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine
23. p70 S6 kinase: An enigma with variations
24. The modular phosphorylation and activation of p70s6k
25. NF-kappa B activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T cell stimulation
26. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients
27. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial
28. A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant patients at risk for primary infection
29. Signalling through the lipid products of phosphoinositide-3-OH kinase
30. CMVIG favorably affect long-term outcome after heart, heart-lung and lung transplantation
31. The PI3K-PDK1 connection: More than just a road to PKB
32. Signaling by distinct classes of phosphoinositide 3-kinases
33. E2F mediates dihydrofolate reductase promoter activation and multi-protein complex formation in human cytomegalovirus infection
34. The human cytomegalovirus UL94 open reading frame encodes a conserved herpesvirus capsid/tegument-associated virion protein that is expressed with true late kinetics
35. Human cytomegalovirus binding to human monocytes induces immunoregulatory gene expression
36. Human cytomegalovirus upregulates NF-κ B activity by transactivating the NF-kappa B p105/p50 and p65 promoters
37. The human cytomegalovirus UL55 (gB) and UL75 (gH) glycoprotein ligands initiate the rapid activation of Sp1 and NF-κB during infection
38. Induction of the transcription factor Sp1 during human cytomegalovirus infection mediates upregulation of the p65 and p105/p50 NF-κB promoters